In addition, HER3 signaling is associated with resistance to the EGFR-targeted TKIs gefitinib in head and neck squamous cell carcinoma (HNSCC) and BC [57, 58]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.